
Talk Is Cheap: Now Trump Must Deliver On His Healthcare Promises
President Donald Trump, accompanied by Health and Human Services Secretary Robert F. Kennedy Jr. ... More (R), holds up an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, D.C.
President Donald Trump has made big promises about fixing American healthcare. Now comes the moment that separates talk from action.
With the 2026 midterms fast approaching and congressional attention soon shifting to electoral strategy, the window for legislative results is closing quickly. This summer will determine whether the administration turns promises into policy or lets the opportunity slip away.
Trump and his handpicked healthcare leaders — HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary — have identified three major priorities: lowering drug prices, reversing chronic disease and unleashing generative AI. Each one, if achieved, would save tens of thousands of lives and reduce costs.
But promises are easy. Real change requires political will and congressional action. Here are three tests that Americans can use to gauge whether the Trump administration succeeds or fails in delivering on its healthcare agenda.
Americans pay two to four times more for prescription drugs than citizens in other wealthy nations. This price gap has persisted for more than 20 years and continues to widen as pharmaceutical companies launch new medications with average list prices exceeding $370,000 per year.
Today, nearly 30% of U.S. prescriptions go unfilled due to cost, leaving millions without the medications they need.
One key reason for the disparity is a 2003 law that prohibits Medicare from negotiating prices directly with drug manufacturers. Although the Inflation Reduction Act of 2022 granted limited negotiation rights, the initial round of price reductions did little to close the gap with other high-income nations.
President Trump has repeatedly promised to change that. In his first term, and again in May 2025, he condemned foreign 'free riders,' promising, 'The United States will no longer subsidize the healthcare of foreign countries and will no longer tolerate profiteering and price gouging.'
To support these commitments, the president signed an executive order titled 'Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.' The order directs HHS to develop and communicate MFN price targets to pharmaceutical manufacturers, with the hope that they will voluntarily align U.S. drug prices with those in other developed nations. Should manufacturers fail to make significant progress toward these targets, the administration said it plans to pursue additional measures, such as facilitating drug importation and imposing tariffs. However, implementing these measures will most likely require congressional legislation and will encounter substantial legal and political challenges.
The pharmaceutical industry knows that without congressional action, there is no way for the president to force them to lower prices. And they are likely to continue to appeal to Americans by arguing that lower prices will restrict innovation and lifesaving drug development.
But the truth about drug 'innovation' is in the numbers: According to a study by America's Health Insurance Plans, seven out of 10 of the largest pharmaceutical companies spend more on sales and marketing than on research and development. And if drugmakers want to invest more in R&D, they can start by requiring peer nations to pay their fair share — rather than depending so heavily on U.S. patients to foot the bill.
If Congress fails to act, the president has other tools at his disposal. One effective step would be for the FDA to redefine 'drug shortages' to include medications priced beyond the reach of most Americans. That change would enable compounding pharmacies to produce lower-cost alternatives just as they did recently with GLP-1 weight-loss injections.
If no action is taken, however, and Americans continue paying more than twice as much as citizens in other wealthy nations, the administration will fail this crucial test.
Obesity has become a leading health threat in the United States, surpassing smoking and opioid addiction as a cause of death.
Since 1980, adult obesity rates have surged from 15% to over 40%, contributing significantly to chronic diseases, including type 2 diabetes, heart disease and multiple types of cancers.
A major driver of this epidemic is the widespread consumption of ultra-processed foods: products high in added sugar, unhealthy fats and artificial additives. These foods are engineered to be hyper-palatable and calorie-dense, promoting overconsumption and, in some cases, addictive eating behaviors.
RFK Jr. has publicly condemned artificial additives as 'poison' and spotlighted their impact on children's health. In May 2025, he led the release of the White House's Make America Healthy Again (MAHA) report, which identifies ultra-processed foods, chemical exposures, lack of exercise and excessive prescription drug use as primary contributors to America's chronic disease epidemic. But while the report raises valid concerns, it has yet to produce concrete reforms.
To move from rhetoric to results, the administration will need to implement tangible policies. Here are three approaches (from least difficult to most) that, if enacted, would signify meaningful progress:
These measures will doubtlessly face fierce opposition from the food and agriculture industries. But if the Trump administration and Congress manage to enact even one of these options — or an equivalent reform — they can claim success. If, instead, they preserve the status quo, leaving Americans to decipher nutritional fine print on the back of the box, obesity will continue to rise, and the administration will have failed.
The Trump administration has signaled a strong commitment to using generative AI across various industries, including healthcare. At the AI Action Summit in Paris, Vice President JD Vance made the administration's agenda clear: 'I'm not here this morning to talk about AI safety ... I'm here to talk about AI opportunity.'
FDA Commissioner Dr. Marty Makary has echoed that message with internal action. After an AI-assisted scientific review pilot program, he announced plans to integrate generative AI across all FDA centers by June 30.
But internal efficiency alone won't improve the nation's health. The real test is whether the administration will help develop and approve GenAI tools that expand clinical access, improve outcomes and reduce costs.
To these ends, generative AI holds enormous promise:
These breakthroughs aren't theoretical. They're achievable. But they won't happen unless federal leaders facilitate broad adoption.
That will require investing in innovation. The NIH must provide funding for next-generation GenAI tools designed for patient empowerment, and the FDA will need to facilitate approval for broad implementation. That will require modernizing current regulations. The FDA's approval process wasn't built for probabilistic AI models that rely on continuous application training and include patient-provided prompts. Americans need a new, fit-for-purpose framework that protects patients without paralyzing progress.
Most important, federal leaders must abandon the illusion of zero risk. If American healthcare were delivering superior clinical outcomes, managing chronic disease effectively and keeping patients safe, that would be one thing. But medical care in the United States is far from that reality. Hundreds of thousands of Americans die annually from poorly controlled chronic diseases, medical errors and misdiagnoses.
If generative AI technology remains confined to billing support and back-office automation, the opportunity to transform American healthcare will be lost. And the administration will have failed to deliver on this promise.
When I teach strategy at Stanford's Graduate School of Business, I tell students that the best leaders focus on a few high-priority goals with clear definitions of success — and a refusal to accept failure. Based on the administration's own words, grading the administration on these three healthcare tests will fulfill those criteria.
However, with Labor Day just months away, the window for action will soon close. The time for presidential action is now.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
14 minutes ago
- CBS News
Trump and Hegseth to visit Fort Bragg as they send troops to Los Angeles
Washington — President Trump and Defense Secretary Pete Hegseth are visiting Fort Bragg, the nation's largest military installation, on Tuesday, after sending the National Guard and U.S. Marines to respond to protests in Los Angeles. Members of the Marine Corps arrived in the greater Los Angeles area Tuesday, a defense official told CBS News, after the military activated about 700 active-duty Marines Monday. The Pentagon said the Marines would "seamlessly integrate" with National Guard troops to protect "federal personnel and federal property." There are 2,100 members of the California National Guard now on location in the greater Los Angeles area, operating in Los Angeles, Paramount and Compton. The president is expected to speak at Fort Bragg in North Carolina around 4 p.m. Hegseth is heading to the military base after testifying on Capitol Hill. "Will be going to Fort Bragg today. Big speech, amazing crowd! See you later!!!" Mr. Trump wrote on Truth Social Tuesday morning. The president claimed Tuesday morning that Los Angeles would be "would be burning to the ground right now," if not for his actions to federalize the National Guard. A memorandum the president signed Saturday said the troops are authorized to protect Immigration and Customs Enforcement officials and other federal law enforcement officials. He invoked Title 10, the U.S. code governing use of the armed forces, allowing the National Guard to come into LA in a supporting role. On Monday, California Gov. Gavin Newsom sued the president and Hegseth over the decision to deploy the National Guard to the state against Newsom's wishes. Newsom argued that Title 10 "has been invoked on its own only once before and for highly unusual circumstances not presented here." He pointed to the text of the U.S. code, which states that when the president calls a state's National Guard into federal service under Title 10, "those orders 'shall be issued through the governors of the States.'" Hegseth, Newsom maintained, "unlawfully bypassed the Governor of California, issuing an order that by statute must go through him." "At no point in the past three days has there been a rebellion or an insurrection," the lawsuit reads. "Nor have these protests risen to the level of protests or riots that Los Angeles and other major cities have seen at points in the past, including in recent years."


American Military News
15 minutes ago
- American Military News
700 Marines deployed to Los Angeles amid major riots
President Donald Trump's administration deployed 700 Marines to Los Angeles and the surrounding area on Monday in response to the city's massive riots against U.S. Immigration and Customs Enforcement (ICE) operations. In a Monday press release, U.S. Northern Command announced that it had activated the Marine infantry battalion that the Trump administration 'placed in an alert status over the weekend.' 'Approximately 700 Marines with 2nd Battalion, 7th Marines, 1st Marine Division will seamlessly integrate with the Title 10 forces under Task Force 51 who are protecting federal personnel and federal property in the greater Los Angeles area,' U.S. Northern Command stated. 'The activation of the Marines is intended to provide Task Force 51 with adequate numbers of forces to provide continuous coverage of the area in support of the lead federal agency.' According to the press release, Task Force 51 includes 700 active-duty Marines and roughly 2,100 National Guardsmen in Title 10 status. Northern Command noted that members of Task Force 51 have been trained in 'de-escalation, crowd control, and standing rules for the use of force.' 'Due to increased threats to federal law enforcement officers and federal buildings, approximately 700 active-duty U.S. Marines from Camp Pendleton are being deployed to Los Angeles to restore order,' Secretary of Defense Pete Hegseth wrote in a statement on X, formerly Twitter. 'We have an obligation to defend federal law enforcement officers – even if Gavin Newsom will not.' READ MORE: Videos: 500 Marines ready to deploy to Los Angeles amid major riots Northern Command confirmed in the press release that there were roughly 1,700 soldiers from the 79th Infantry Brigade Combat Team in Los Angeles and the surrounding area as of Monday. On Monday evening, Assistant to the Secretary of Defense for Public Affairs Sean Parnell tweeted, 'At the order of the President, the Department of Defense is mobilizing an additional 2,000 California National Guard to be called into federal service to support ICE & to enable federal law-enforcement officers to safely conduct their duties.' According to The Associated Press, Trump's authorization for the Department of Defense to deploy an additional 2,000 National Guardsmen in response to the anti-ICE riots in Los Angeles brings the total number of National Guardsmen mobilized by the federal government in response to the riots to over 4,100. In a Tuesday morning statement on Truth Social, Trump said, 'If I didn't 'SEND IN THE TROOPS' to Los Angeles the last three nights, that once beautiful and great City would be burning to the ground right now, much like 25,000 houses burned to the ground in L.A. do to an incompetent Governor and Mayor.'


CNBC
20 minutes ago
- CNBC
Why Elon Musk turned against Trump's $5 trillion mega tax and spending bill
President Donald Trump is pushing to pass a sweeping tax and spending bill by July 4, but the proposal is already sparking fierce internal GOP debate. The bill combines 2017 tax cut extensions with new Trump-era proposals, including deductions on American-made auto loans and changes to child tax credits. But not everyone is on board. Elon Musk has launched a high-profile feud with Trump over the bill, and key Republican senators are warning that the bill could add trillions to the national debt.